PVLA
The table below shows Palvella Therapeutics, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | $0.00 | $0.00 |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $9.33M | $6.53M | $5.12M | $4.07M | $3.18M | $1.44M |
| SG&A |
Palvella Therapeutics, Inc. reported annual revenue of $42.81M for fiscal year 2023. That is up 65.3% from $25.90M in fiscal 2022. Over the 10 fiscal years shown, annual revenue grew from $5.37M (FY 2014) to $42.81M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $5.52M |
| $3.65M |
| $4.13M |
| $3.80M |
| $1.88M |
| $1.47M |
| Operating income | -$14.86M | -$10.18M | -$9.25M | -$7.87M | -$5.06M | -$2.91M |
| Income tax | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$15.77M | -$11.35M | -$9.47M | -$8.19M | -$6.78M | -$4.17M |
| EPS (diluted) | -$1.20 | -$1.03 | -$0.86 | -$0.74 | -$3.94 | -$2.47 |